Alnylam Pharmaceuticals, Inc.
ALNY- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001178670
No open-market purchases or sales by Alnylam Pharmaceuticals, Inc. insiders were filed in the last 90 days; 794 institutions reported holding it in 13F filings for Q2 2026, worth $40.1B in total; no superinvestor holds it.
Superinvestors holding ALNY, Q2 2026
No superinvestor reported holding ALNY in Q2 2026.
Moves by quarter
Superinvestors that opened, added to, trimmed or sold out of ALNY each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.
Q4 2025
0 superinvestors holding at quarter end
- Sold out
- Soros Fund Management
Q3 2025
1 superinvestor holding at quarter end
Q2 2025
0 superinvestors holding at quarter end
- Sold out
- Soros Fund Management
Q1 2025
1 superinvestor holding at quarter end
Q1 2023
0 superinvestors holding at quarter end
- Sold out
- Duquesne Family Office
Q3 2022
1 superinvestor holding at quarter end
Q2 2022
0 superinvestors holding at quarter end
- Sold out
- Duquesne Family Office
Q1 2022
1 superinvestor holding at quarter end
Q4 2021
0 superinvestors holding at quarter end
- Sold out
- Maverick Capital
Q3 2021
1 superinvestor holding at quarter end
- Reduced
- Maverick Capital (−98.6%)
Q2 2021
1 superinvestor holding at quarter end
- Reduced
- Maverick Capital (−63.2%)